Login / Signup

Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides.

Jiao LuoMeiling ZhengBo JiangChao LiShuju GuoLijun WangXiangqian LiRilei YuDayong Shi
Published in: British journal of pharmacology (2020)
BDB application offers a potentially practical pharmacological approach for treating Type 2 diabetes mellitus by selectively inhibiting PTP1B.
Keyphrases
  • signaling pathway
  • glycemic control
  • protein protein
  • amino acid
  • binding protein
  • type diabetes
  • cardiovascular risk factors
  • protein kinase
  • cardiovascular disease
  • adipose tissue
  • insulin resistance
  • skeletal muscle